Volume 21 Issue 2
Feb.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(2): 238-241
LAN Wu-yuan, HU Wei-ming, LAN Zhi-yong. Clinical efficacy of pharmacogenomic testing in patients with refractory schizophrenia[J]. Chinese Journal of General Practice, 2023, 21(2): 238-241. doi: 10.16766/j.cnki.issn.1674-4152.002854
Citation: LAN Wu-yuan, HU Wei-ming, LAN Zhi-yong. Clinical efficacy of pharmacogenomic testing in patients with refractory schizophrenia[J]. Chinese Journal of General Practice, 2023, 21(2): 238-241. doi: 10.16766/j.cnki.issn.1674-4152.002854
shu

Clinical efficacy of pharmacogenomic testing in patients with refractory schizophrenia

doi: 10.16766/j.cnki.issn.1674-4152.002854

  • Department of Male Psychiatry, Quzhou Third Hospital, Quzhou, Zhejiang 324000, China

Funds:

 2022KY1352

  • Received Date: 2022-10-18
    Available Online: 2023-04-20
    Abstract
  •   Objective  This study aims to improve the efficacy and safety of drug use in patients with refractory schizophrenia, this paper focuses on the application of pharmacogenomic testing in refractory schizophrenia.  Methods  A total of 100 male patients with refractory schizophrenia who were diagnosed and treated in Quzhou Third Hospital from November 2021 to September 2022 were included in this study. The patients were divided into control group (based on doctors' experience) and observation group (based on pharmacogenetic testing) according to the random number table method, with 50 cases in each group. The clinical efficacy, insight, quality of life, social adaptation at 1 month and 1 year after discharge, recurrence rate and adverse reaction rate between the two groups were compared.  Results  After 1 month of treatment, all symptom types (positive, negative, and general psychopathological symptom) in the observation group were lower than those in the control group [(20.11±2.67) points vs. (23.89±3.10) points, (15.02±1.88) points vs. (18.27±2.33) points, (30.35±2.93) points vs. (35.24±3.80) points, all P < 0.001]; the scores of schedule for assessing insight (SAI) and 36 item short form (SF-36) in the observation group were significantly higher than those in the control group [(10.27±1.71) points vs. (7.24±1.62) points, (88.06±18.37) points vs. (73.41±16.82) points, both P < 0.001]. At 1 month and 1 year after discharge, the personal and social functioning scale (PSP)score of the observation group was significantly higher than that of the control group [(68.30±6.10) points vs. (59.24±5.68) points, (81.32±7.30) points vs. (75.49±6.29) points, both P < 0.001]. The incidence of drug-related adverse reactions in the observation group was significantly lower than that in the control group (P < 0.05). One year after discharge, the recurrence rate in the observation group was significantly lower than that in the control group (P < 0.001).  Conclusion  It has obvious advantages to guide the clinical medication of refractory schizophrenia according to the results of pharmacogenomic testing. Patients not only have high compliance and fast symptom relief, but also can promote the quality of life, social adaptability, reduce the recurrence rate and adverse reaction rate, which is worthy of clinical promotion.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    郝伟, 陆林. 精神病学[M]. 8版. 北京: 人民卫生出版社, 2018: 85-96.

    HAO W, LU Lin. Psychiatry[M]. 8th ed. Beijing: People's Medical Publishing House, 2018: 85-96.
    [2]
    DE BARTOLOMEIS A, VELLUCCI L, BARONE A, et al. Clozapine's multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia[J]. Pharmacol Ther, 2022, 236: 108236. DOI: 10.1016/j.pharmthera.2022.108236.
    [3]
    赵靖平, 施慎逊. 中国精神分裂症防治指南[M]. 2版. 北京: 中华医学电子音像出版社, 2015: 121-123.

    ZHAO J P, SHI S X. Guidelines for schizophrenia Prevention and Treatment in China[M]. 2ed ed. Beijing: China Medical Electronic Audio and Video Publishing House, 2015: 121-123.
    [4]
    余林花, 王铁虎. 复发性精神分裂症患者生活质量状况调查及影响因素分析[J]. 中华全科医学, 2022, 20(5): 821-823, 858. doi: 10.16766/j.cnki.issn.1674-4152.002463

    YU L H, WANG T H. Quality of life in patients with recurrent schizophrenia and analysis of influencing factors[J]. Chinese Journal of General Practice, 2022, 20(5): 821-823, 858. doi: 10.16766/j.cnki.issn.1674-4152.002463
    [5]
    ZAMANPOOR M. Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights[J]. Psychiatr Genet, 2020, 30(1): 1-9. doi: 10.1097/YPG.0000000000000245
    [6]
    岳伟华, 王强. 药物基因组学在精神分裂症精准医疗中的应用[J]. 中华精神科杂志, 2020, 53(6): 469-472. doi: 10.3760/cma.j.cn113661-20200328-00150

    YUE W H, WANG Q. Application of pharmacogenomics in precision medicine of schizophrenia[J]. Chinese Journal of Psychiatry, 2020, 53(6): 469-472. doi: 10.3760/cma.j.cn113661-20200328-00150
    [7]
    杨朝晖, 索冠伟. 最新国际疾病分类精神分裂症和其他原发性精神障碍精神症状评定进展[J]. 中国神经精神疾病杂志, 2018, 44(1): 55-57. doi: 10.3969/j.issn.1002-0152.2018.01.012

    YANG Z H, SUO G W. Progress in the assessment of psychiatric symptoms of schizophrenia and other primary mental disorders in the latest International Classification of Diseases[J]. Chinese Journal of Nervous and Mental Diseases, 2018, 44(1): 55-57. doi: 10.3969/j.issn.1002-0152.2018.01.012
    [8]
    CORRELL C U, DAVIS R E, WEINGART M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial[J]. JAMA Psychiatry, 2020, 77(4): 349-358. doi: 10.1001/jamapsychiatry.2019.4379
    [9]
    ITO S, MATSUMOTO J, SAKAI Y, et al. Positive association between insight and attitudes toward medication in Japanese patients with schizophrenia: evaluation with the Schedule for Assessment of Insight (SAI) and the Drug Attitude Inventory-10 Questionnaire (DAI-10)[J]. Psychiatry Clin Neurosci, 2021, 75(5): 187-188. doi: 10.1111/pcn.13215
    [10]
    KOSSMANN C, HELLER J, BRVNE M, et al. Assessment of psychosocial functioning in a large cohort of patients with schizophrenia[J]. Psychiatr Q, 2021, 92(1): 177-191. doi: 10.1007/s11126-020-09773-y
    [11]
    范桂红, 何俊, 庞高峰, 等. 无抽搐电休克疗法对精神分裂症患者的治疗效果和脑内及不同脑区神经递质水平的影响研究[J]. 中国全科医学, 2022, 25(3): 325-330. doi: 10.12114/j.issn.1007-9572.2021.02.027

    FAN G H, HE J, PANG G F, et al. Modified electroconvulsive therapy in patients with schizophrenia: curative effect and responses of neurotransmitters in brain and different brain regions[J]. Chinese General Practice, 2022, 25(3): 325-330. doi: 10.12114/j.issn.1007-9572.2021.02.027
    [12]
    郎小娥, 薛晓燕, 侯鑫, 等. 低剂量齐拉西酮联合低剂量舍曲林治疗难治性精神分裂症的疗效和安全性研究[J]. 中西医结合心脑血管病杂志, 2020, 18(9): 1451-1456. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202009026.htm

    LANG X E, XUE X Y, HOU X, et al. Efficacy and safety of low dose Ziprasidone combined with low dose Sertraline in the treatment of refractory schizophrenia[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2020, 18(9): 1451-1456. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202009026.htm
    [13]
    胡维, 乔娟, 刘艳, 等. 治疗抵抗精神分裂症患者细胞色素氧化酶基因多态性分析[J]. 临床精神医学杂志, 2021, 31(1): 54-56. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJS202101017.htm

    HU W, QIAO J, LIU Y, et al. Analysis of cytochrome oxidase gene polymorphism in patients with treatment-resistant schizophrenia[J]. Journal of Clinical Psychiatry, 2021, 31(1): 54-56. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJS202101017.htm
    [14]
    穆晞园, 张晨, 王晓蓉. 精神分裂症患者治疗依从性的相关因素分析[J]. 中华全科医学, 2021, 19(12): 2081-2083. doi: 10.16766/j.cnki.issn.1674-4152.002242

    MU X Y, ZHANG C, WANG X R. Analysis of related factors of treatment compliance in patients with schizophrenia[J]. Chinese Journal of General Practice, 2021, 19(12): 2081-2083. doi: 10.16766/j.cnki.issn.1674-4152.002242
    [15]
    ZHANG Y M, WANG Q, REYNOLDS G P, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-term, randomized, open-label, multicenter, pharmacologic trial[J]. J Clin Psychiatry, 2020, 81(3): 19m12785. DOI: 10.4088/JCP.19m12785.
    [16]
    彭焱, 杨斌, 雷静, 等. 药物基因检测在难治性精神分裂症中的临床应用[J]. 健康必读, 2021(12): 6-7.

    PENG Y, YANG B, LEI J, et al. Clinical application of drug gene detection in refractory schizophrenia[J]. Health Must Reading Magazine, 2021(12): 6-7.
    [17]
    由炜, 丁宁, 李智强, 等. 团体归因训练与氯氮平联合治疗对难治性精神分裂症患者阴性症状及生活质量的作用[J]. 中华行为医学与脑科学杂志, 2019, 28(6): 538-542.

    YOU W, DING N, LI Z Q, et al. Effect of group attribution training combined with clozapine on negative symptoms and quality of life in refractory schizophrenia patients[J]. Chinese Journal of Behavioral Medicine and Brain Science, 2019, 28(6): 538-542.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (232) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return